Assays Evaluated for Early Diagnosis of Leptospirosis
|
By LabMedica International staff writers Posted on 11 Jul 2017 |

Image: The ImmunoDOT is a proprietary dotblot method reporting a semi-quantitative IgM titer for leptospirosis (Photo courtesy of GenBio).
Leptospirosis is a potentially life-threatening but curable zoonosis whose prognosis depends on accurate and timely diagnosis and because of its non-specific clinical presentation, laboratory testing is essential to confirm the diagnosis.
Leptospirosis is caused by pathogenic spirochetes of the genus Leptospira. With an estimated 1.03 million cases and 58,900 deaths occurring each year, leptospirosis represents a major threat to public health worldwide. Severity ranges from relatively mild flu-like symptoms to Weil’s syndrome, a severe and potentially life-threatening form of the disease characterized by multiple organ failure, including the liver, kidneys, lungs, heart and brain.
Microbiologists at the University Hospital of Fort-de-France (Martinique, French West Indies) and their colleagues conducted a retrospective study between January 2011 and December 2012 of a total of 122 patients were diagnosed with leptospirosis, as confirmed by quantitative polymerase chain reaction (qPCR). Among them, 103 had at least one serum sample available for analysis. Performance of each serological assay was evaluated according to days' post onset of symptoms (DPO) and local species diversity.
Blood plasma samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes obtained from patients with clinically suspected leptospirosis. Serum specimens were collected in plastic red-top tubes at different times during the course of the illness and stored at -20 °C until testing. The team assessed the performance of two enzyme-linked immunosorbent assays (ELISAs): ELISA Serion and ELISA-Hb Pasteur and one immunodot using qPCR as the gold standard.
The scientists reported the sensitivity of ELISA Serion, ELISA-Hb Pasteur and GenBio immunodot was 75%, 67% and 64%, while specificity was 92%, 98% and 100%, respectively. Moreover, the threshold optimization allowed a significant improvement in specificity for the ELISA Serion from 92% to 99%. During the first five DPO, sensitivities were 35%, 30% and 42% for ELISA Serion, ELISA-Hb Pasteur and GenBio immunodot, respectively. However, between six to 10 DPO, these sensitivities dramatically increased to reach 86%, 76% and 67%, respectively. Performances of the three assays were not affected by the species studied.
The authors concluded that all the serological assays evaluated showed the potential for diagnosing leptospirosis after, but not before six days’ post onset of symptoms. In a high prevalence setting, where highest specificities are needed, threshold optimizing should be performed for this purpose. The combination of serology and qPCR could be the most reliable approach for laboratory confirmation of clinically suspected cases of leptospirosis in resource-limited settings, easy handling and cost-effectiveness may be the main decision factors to choose between assays with similar accuracy for routine use. The study was published on June 23, 2017, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
University Hospital of Fort-de-France
Leptospirosis is caused by pathogenic spirochetes of the genus Leptospira. With an estimated 1.03 million cases and 58,900 deaths occurring each year, leptospirosis represents a major threat to public health worldwide. Severity ranges from relatively mild flu-like symptoms to Weil’s syndrome, a severe and potentially life-threatening form of the disease characterized by multiple organ failure, including the liver, kidneys, lungs, heart and brain.
Microbiologists at the University Hospital of Fort-de-France (Martinique, French West Indies) and their colleagues conducted a retrospective study between January 2011 and December 2012 of a total of 122 patients were diagnosed with leptospirosis, as confirmed by quantitative polymerase chain reaction (qPCR). Among them, 103 had at least one serum sample available for analysis. Performance of each serological assay was evaluated according to days' post onset of symptoms (DPO) and local species diversity.
Blood plasma samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes obtained from patients with clinically suspected leptospirosis. Serum specimens were collected in plastic red-top tubes at different times during the course of the illness and stored at -20 °C until testing. The team assessed the performance of two enzyme-linked immunosorbent assays (ELISAs): ELISA Serion and ELISA-Hb Pasteur and one immunodot using qPCR as the gold standard.
The scientists reported the sensitivity of ELISA Serion, ELISA-Hb Pasteur and GenBio immunodot was 75%, 67% and 64%, while specificity was 92%, 98% and 100%, respectively. Moreover, the threshold optimization allowed a significant improvement in specificity for the ELISA Serion from 92% to 99%. During the first five DPO, sensitivities were 35%, 30% and 42% for ELISA Serion, ELISA-Hb Pasteur and GenBio immunodot, respectively. However, between six to 10 DPO, these sensitivities dramatically increased to reach 86%, 76% and 67%, respectively. Performances of the three assays were not affected by the species studied.
The authors concluded that all the serological assays evaluated showed the potential for diagnosing leptospirosis after, but not before six days’ post onset of symptoms. In a high prevalence setting, where highest specificities are needed, threshold optimizing should be performed for this purpose. The combination of serology and qPCR could be the most reliable approach for laboratory confirmation of clinically suspected cases of leptospirosis in resource-limited settings, easy handling and cost-effectiveness may be the main decision factors to choose between assays with similar accuracy for routine use. The study was published on June 23, 2017, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
University Hospital of Fort-de-France
Latest Microbiology News
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreMolecular Diagnostics
view channel
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more








